IPO - Pasithea Therapeutics Corp.

Form Type: 424B4

Filing Date: 2025-05-07

Corporate Action: Ipo

Type: New

Accession Number: 000121390025040438

Filing Summary: Pasithea Therapeutics Corp. is offering up to 3,094,284 shares of common stock, alongside pre-funded warrants to purchase 477,144 shares and common warrants to purchase up to 7,142,856 shares. The offering includes both Series C and Series D Common Warrants with an exercise price of $1.40. The shares and warrants are immediately separable and must be purchased together, priced at $1.40 per share or $1.399 for each pre-funded warrant. The offering is set to terminate on May 31, 2025, unless ended sooner at the company's discretion. The firm has contracted H.C. Wainwright & Co., LLC as the placement agent. The expected delivery date for the securities is May 7, 2025. The company is classified as an emerging growth company and smaller reporting company, which allows for reduced reporting requirements.

Form Type: CORRESP

Filing Date: 2025-05-01

Corporate Action: Ipo

Type: New

Accession Number: 000121390025038338

Filing Summary: Pasithea Therapeutics Corp. has submitted a request for the Securities and Exchange Commission to take action on its Registration Statement on Form S-1, with the goal of having it become effective on May 5, 2025. H.C. Wainwright & Co., LLC. acts as the placement agent, affirming adherence to its obligations under the Securities Act regarding the best-efforts offering related to the registration.